Retatrutide and trizepatide are a novel class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists exhibit https://nicolasuqdp871913.liberty-blog.com/profile